NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. [electronic resource]
Producer: 20160104Description: 98-110 p. digitalISSN:- 2211-1247
- Adenocarcinoma -- drug therapy
- Adenocarcinoma of Lung
- Antineoplastic Agents -- administration & dosage
- Apoptosis -- drug effects
- Cell Line, Tumor
- Cell Survival -- drug effects
- Cyclohexanones -- administration & dosage
- Drug Resistance, Neoplasm -- genetics
- Epoxy Compounds -- administration & dosage
- ErbB Receptors -- antagonists & inhibitors
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- I-kappa B Kinase -- genetics
- Lung Neoplasms -- drug therapy
- Molecular Targeted Therapy
- NF-kappa B -- antagonists & inhibitors
- Nuclear Pore Complex Proteins -- genetics
- Proto-Oncogene Proteins c-akt -- genetics
- RNA-Binding Proteins -- genetics
- Signal Transduction -- drug effects
- TNF Receptor-Associated Factor 2 -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.